8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

May 14, 2002

(Date of earliest event reported)

SANGSTAT MEDICAL CORPORATION
(Exact name of Registrant as specified in its charter)
Delaware	0-22890	94-3076-069
(State of incorporation or organization)	(Commission File No.)	(IRS Employer Identification No.)
6300 Dumbarton Circle Fremont, CA 94555
(Address of principal executive offices)
(510) 789-4300
(Registrant’s telephone number, including area code)

Item 5. Other Events.

SangStat Medical Corporation (the “Company”) announced the election of Hollings C. Renton to its Board of Directors at the Company’s Annual Meeting of Stockholders held on May 14, 2002.  The Company issued a press release dated May 14, 2002, announcing the election of Mr. Renton, which is filed herewith as Exhibit 99.1.

Item 7.	Exhibits.
	(a)           Not applicable
	(b)           Not applicable
	(c)           Exhibits

Exhibit No.	Description
99.1	Press release dated May 14, 2002

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SANGSTAT MEDICAL CORPORATION
	By:	/s/ Stephen G. Dance
		Stephen G. Dance
Date:  May 22, 2002		Senior Vice President, Finance

3

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press release dated May 14, 2002

4

EX-99

Exhibit 99.1

Contact:	Bill Martin
	510-789-4331

FOR IMMEDIATE RELEASE

HOLLINGS C. RENTON JOINS SANGSTAT BOARD OF DIRECTORS

Fremont, Calif. - May 14, 2002 - SangStat (Nasdaq: SANG) announced today that Hollings C. Renton has been elected to its Board of Directors. Mr. Renton has served as the President and Chief Executive Officer of Onyx Pharmaceuticals, Inc., a public biotechnology company, since March 1993. He has served on its Board since 1992 and currently is the Chairman.

“We are very fortunate to have someone with Mr. Renton’s leadership experience join our board,” said Jean-Jacques Bienaimé, Chairman, President and CEO of SangStat. “SangStat will benefit from Mr. Renton’s extensive general management experience within large established biotechnology corporations and also in smaller entrepreneurially-oriented organizations.”

Prior to joining Onyx, Mr. Renton served as President and Chief Operating Officer of Chiron Corporation, a public biotechnology company, from December 1991 following Chiron Corporation’s acquisition of Cetus Corporation, a biopharmaceutical company. Prior to the acquisition, Mr. Renton served as President of Cetus Corporation from August 1990 to December 1991 and as Chief Operating Officer of Cetus Corporation from 1987 to August 1990. He is also a director of Cepheid, a public DNA diagnostics company. Mr. Renton holds a B.S. in Mathematics from Colorado State University and an M.B.A. from the University of Michigan.

SangStat

SangStat is a global biotechnology company focused on immunology and working to discover, develop and market high value therapeutic products in the autoimmune, hematology/oncology and immunosuppression areas. SangStat’s U.S. headquarters are in Fremont, California. SangStat also maintains a strong European presence, including direct sales and marketing forces in France, Germany, Italy, Spain, and the UK, and distributors throughout the rest of the world. SangStat’s stock is traded on the Nasdaq under the symbol “SANG.” The company’s web site is located at www.sangstat.com.

This press release contains “forward-looking” statements. For this purpose, any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “will,” “intends” and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause results to differ materially from those indicated by these forward-looking statements. For a discussion of these and other factors that might result in different outcomes, see “Risk Factors” in SangStat’s 2001 Annual Report on Form 10-K, its 2002 quarterly reports on Form 10-Q, and other documents (including registration statements and related prospectuses on Form S-3) filed with the Securities and Exchange Commission. SangStat assumes no obligation to update any such forward-looking statements, risks or reasons why actual results might differ.

# # #